Improving CAR T-Cell Therapies for Multiple Myeloma: Thomas G. Martin, MD
The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed CAR T-cell therapies and safety signals of cilta-cel.
The Need for Analysis in Lentiviral Cell Therapies: Luca Biasco, PhD
The director of research and development at AVROBIO discussed the analytical pipeline the company has developed for molecular follow-up of cell therapies.
The Potential Impact of Gene and Cell Therapy in Cystinosis: Stephanie Cherqui, PhD
The associate professor from UC San Diego discussed the curative potential of gene therapy in cystinosis.
Achieving Remission in Chronic Lymphocytic Leukemia With CD4+ CAR T-Cells: Jan Joseph Melenhorst, PhD
The translational immunologist and research professor at Perelman School of Medicine, University of Pennsylvania, discussed persistence of CD4+ CAR T-cells in CLL.
Latest Updates on Geographic Atrophy Gene Therapy FOCUS Trial: Nadia K. Waheed, MD
The associate professor from Tufts University School of Medicine discussed the latest updates on the FOCUS trial.
Achieving Developmental Milestones With GM1 Gangliosidosis Gene Therapy: David Weinstein, MD
The senior vice president of clinical development at Passage Bio discussed new data from the IMAGINE-1 trial presented at WORLDSymposium.
Fibroblast Cell Therapy or Stem Cell Therapy for MS: Hamid Khoja, PhD
The chief scientific officer of FibroBiologics discussed the advantages of fibroblast cell therapy over stem cell therapy.
Treating Solid Tumors With Personalized Immunotherapy: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors.
The Importance of Collaboration in Developing Next Generation Cell Therapies
Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed the company’s collaboration with 2seventy bio to develop TCR T-cell therapies.
Assessing EtranaDez for Hemophilia B in HOPE-B: Wolfgang Miesbach, MD, PhD
The professor and head of coagulation disorders and Comprehensive Care Centre, University Hospital of Frankfurt, Germany, discussed results of the final analysis of the HOPE-B study.
Assessing Fitusiran for Hemophilia in ATLAS-INH: Guy Young, MD
The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed the ATLAS-INH trial.
Challenges in Managing Hemophilia: Steven W. Pipe, MD
The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed challenges in hemophilia A and B.
Assessing Gene Therapy in Recessive Dystrophic Epidermolysis Bullosa
Matthew Gantz, president and chief executive officer, Castle Creek Biosciences, discussed the company and its pipeline.
Tumor-Infiltrating Lymphocyte Therapy After Immunotherapy in Advanced Melanoma: Omid Hamid, MD
The director of the Melanoma Program at Cedars-Sinai Medical Center discussed the efficacy of TIL therapy following immunotherapy in advanced melanoma.
Brexucabtagene Autoleucel in R/R Mantle Cell Lymphoma
Experts discussed the ZUMA-2 clinical trial of brexucabtagene autoleucel.
Evaluation Criteria for TIL Therapy in Melanoma: Omid Hamid, MD
The director of the Melanoma Program at Cedars-Sinai Medical Center discussed evaluation criteria for TIL therapy in melanoma.
Cilta-Cel in the Multiple Myeloma Treatment Landscape: Thomas G. Martin, MD
The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from both the CARTITUDE-1 and CARTITUDE-2 studies.
Expanding Study Populations of Cell Therapy in Sickle Cell Disease: Michael Grimley, MD
The medical director of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's discussed data on ARU-1801 presented at ASH 2021.
Challenges of Cell Therapy in Solid Tumors: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod cell therapy in solid tumors.
Selecting Targets in Hematologic Malignancies
Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed MDG1011 and Medigene’s future research and targets.
Evaluating MB-106 in B-NH Lymphoma and CL Leukemia: Mazyar Shadman, MD
The associate professor from Fred Hutchinson Cancer Research Center discussed the methods utilized in an ongoing phase 1/2 trial evaluating MB-106.
Improving Outcomes in Hemophilia With Fitusiran: Guy Young, MD
The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed advantages of the siRNA therapeutic.
Improving Outcomes in Corneal Endothelial Disease With Cell Therapy
Greg Kunst, chief executive officer, Aurion Biotech, discussed the potential of cell therapy in treating people with corneal endothelial disease around the world.
Cilta-Cel's Efficacy in Heavily Pretreated Patients With Multiple Myeloma: Thomas G. Martin, MD
The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from the CARTITUDE-1 study presented at ASH 2021.
Improving Specificity of T-Cell Therapies in Solid Tumors: Julian Molina, MD, PhD
The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod technology in solid tumors.
Increasing CAR T-cell Use in R/R DLBC Lymphoma: Marin F. Xavier, MD; John M. Burke, MD
Experts discuss recommendations to increase the uptake of CAR T-cell therapies into clinical practice and relapsed/refractory diffuse large B-cell lymphoma.
Liso-Cel's Efficacy in R/R Large B-Cell Lymphoma: Michael Wang, MD
The professor from University of Texas MD Anderson Cancer Center discussed the FDA approval of lisocabtagene maraleucel.
Improving Cell Therapies for Hematological Malignancies
Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed the phase 1/2 study evaluating MDG1011.
Reducing Treatment Burden in Hemophilia: Guy Young, MD
The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed improving outcomes in hemophilia with fitusiran.
Further Research With Tab-Cel in EBV+ Post-Transplant Lymphoproliferative Disease
AJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed further research with tab-cel, including study 205.
